"Designing Growth Strategies is in our DNA"

Morquio Syndrome Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy), By Disease Type (Morquio A, Morquio B), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography Forecast till 2021-2028

Region : Global | Report ID: FBI100202 | Status : Ongoing

 

KEY MARKET INSIGHTS

Morquio Syndrome, also known as MPS IV and mucopolysaccharidosis IV, refers to a rare inherited metabolic disorder or birth defect that mostly affects the skeleton. The FDA approval of VIMIZIM (elosulfase alpha), the first and the only specific treatment for the patients with this ultra-rare genetic condition, firmly established BioMarin’s position as a leading market player for the treatment of MPS diseases.


Apart from the recent regulatory approvals, there has been increasing activity in the R&D for the Morquio syndrome treatment as evidenced by the greater inclusion of the disorder in the clinical pipelines of the major market players. For instance, Ultragenyx Pharmaceutical Inc. has a Phase 3 Study undergoing for the Morquio syndrome, Shire has an ongoing clinical trial for the pediatric patients suffering from the syndrome and ArmaGen, Inc. also has a drug (AGT-181) in the clinical trials. This combined with the greater awareness of the disease is also driving the growth in Morquio syndrome treatment market.


To gain extensive insights into the market, Request for Customization


The growth in the number of products in the preliminary and advanced stages of R&D along with the focus on treatment of rare diseases is anticipated to drive the growth in the Morquio syndrome treatment market at a considerably fast rate. With the recent approval of the elosulfase alpha (VIMIZIM), the market is expected to be boosted a number of products currently in the pipelines of various companies can be anticipated to undergo regulatory approvals for the marketing, if they have favourable clinical trials results. 


The factor that is expected to limit the growth of the market is the huge price tag associated with Morquio syndrome treatment products. For example, VIMIZIM is expected to cost patients around US$ 380,000, which is estimated to be the product’s annual cost. Other factors which may limit the growth of the market is the lack of awareness in the emerging markets and the regulatory and the clinical hurdles. 


Key Players Covered 


Some of the major companies that are present in the global Morquio Syndrome Treatment Market are BioMarin, Genzyme Corporation, Shire, JCR Pharmaceuticals Co., Ltd., Sanofi, Sangamo Therapeutics, ArmaGen and GREEN CROSS CORP, Concert Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and other players. 


 SEGMENTATION 


 


























 SEGMENTATION



 DETAILS



By Treatment



·      Enzyme Replacement Therapy


·      Others



By Disease Type



·      Morquio A


·      Morquio B



ByDistribution Channel



·      Hospital Pharmacies


·      Retail Pharmacies


·      Online Pharmacies


·      Others



By Geography



·      North America (USA and Canada)


·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


·      Latin America (Brazil, Mexico and Rest of Latin America)


·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



                       


At present, enzyme replacement therapy accounts for the largest proportion of the market and the trend is expected to remain same during the forecast period due to the approval of elosulfase alpha, the only FDA approved treatment option, is an enzyme replacement therapy. 


Key Insights 



  • Prevalence of Morquio syndrome by key countries

  • Advancements in research & development of treatment options

  • Overview of advancements in novel therapeutics

  • Pricing Analysis by key countries

  • Pipeline Analysis

  • Regulatory scenario by key countries

  • New product launches 


Regional Analysis 


The global Morquio Syndrome Treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Morquio Syndrome Treatment at present and they are expected to account for a large proportion of the market in the forecast period as well. The world’s first and only Morquio Syndrome Treatment, VIMIZIM, received marketing approval in the U.S. and Europe in 2014 and as of date, this is the only specific treatment for Morquio syndrome that is approved by the regulatory authorities. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This was primarily due to the early approval and adoption of VIMIZIM as a treatment option for the Morquio syndrome. 


Key Industry Developments



  • In 2014, Bio Marin’s product offering of VIMIZIM (elosulfase alpha) was approved as the only treatment option for Morquio syndrome across a number of regulatory agencies in the U.S., Europe and Japan

  • In 2017, Sangamo Therapeutics Inc., who have the gene therapy candidate (SB-913) in their clinical pipeline, was granted the rare pediatric disease designation from the FDA

  • Another drug from Sangamo, SB-318 was also granted the orphan drug status from the U.S. FDA 


Morquio Syndrome Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2020
  • 2017-2019

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Roche
Lek
Grifols
iqvia
Ansell

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X